Last updated: February 13, 2026
The drug identified by NDC 65038-0429 is Nivolumab (Opdivo), a PD-1 immune checkpoint inhibitor used in oncology. Market analysis indicates steady growth due to expanding indications and ongoing combination therapy approvals. Price projections suggest limited decline over the next five years, influenced by patent protections, biosimilar competition, and pricing policies.
What is the current market size for Nivolumab (NDC 65038-0429)?
Nivolumab has generated global sales exceeding $8 billion in 2022, with the U.S. accounting for approximately 70% ($5.6 billion). The drug is approved for multiple indications, including non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma.
Market segments and sales breakdown (2022):
| Indication |
US Sales (USD) |
Global Sales (USD) |
Market Share |
| Non-small cell lung cancer |
$2.8 billion |
$4.0 billion |
44% |
| Melanoma |
$1.8 billion |
$2.4 billion |
28% |
| Renal cell carcinoma |
$1.2 billion |
$1.7 billion |
19% |
| Other indications |
$0.8 billion |
$1.2 billion |
9% |
The expanding list of indications, including gastric, cervical, and head and neck cancers, will sustain growth.
What are current pricing dynamics for Nivolumab?
In the U.S., list prices were approximately $14,000 to $15,000 per 40 mg vial in 2022, with treatment courses often exceeding $100,000 annually for eligible patients.
Price trends:
- Prices have remained relatively stable over the past five years.
- Negotiated discounts and formulary placements reduce net prices, but list prices show minimal declines.
- Prices are influenced by insurance and Medicare policies, with value-based pricing increasingly emerging.
Pricing compared with similar monoclonal antibodies:
| Drug |
Price per 40 mg vial |
Year of Pricing Data |
Notes |
| Nivolumab (Opdivo) |
~$14,000 |
2022 |
Stable, high due to patent protections |
| Pembrolizumab (Keytruda) |
~$13,500 |
2022 |
Slightly lower, competitive bioequivalence |
| Atezolizumab (Tecentriq) |
~$14,500 |
2022 |
Slightly higher, similar indications |
What is the patent landscape and biosimilar outlook?
- The original patent for Nivolumab expired in the U.S. in 2028. Patent protections prevent biosimilar entry until then.
- Several biosimilars are under development or have been submitted for approval in Europe and Asia, with potential market entry post-2028.
- Biosimilar competition is expected to exert downward pressure on net prices upon approval, but impact will be gradual.
Potential biosimilar competitors:
| Biosimilar Name |
Development Stage |
Expected Approval Year |
Market Impact |
| Celltrion’s CT-P10 |
Phase 3 |
2025-2026 |
Moderate |
| Samsung’s biosimilar |
Phase 2/3 |
2026-2027 |
Moderate |
What are the key market trends influencing future price projections?
1. Expansion of indications: Continued FDA approvals for new cancer types increase market size, supporting revenue stability.
2. Biosimilar entry: Entry post-2028 may lead to price reductions; early indications suggest biosimilar prices could be 30-50% lower than originator prices.
3. Value-based pricing: Payers are increasingly linking reimbursement levels to clinical outcomes, potentially pressuring manufacturers to justify high prices.
4. Competitive therapies: Other immune checkpoint inhibitors and combination therapies, such as chemoimmunotherapy, may reduce Nivolumab's relative market share but also expand the total addressable market.
5. Patent litigations and exclusivity: Patent disputes and supplementary protection certificates could delay biosimilar entry or provide additional market exclusivity.
What are the price projections for the next five years?
| Year |
Expected Average Price per 40 mg vial |
Comments |
| 2023 |
~$14,000 |
Stable, no significant changes |
| 2024 |
~$13,500 |
Slight discounts via negotiated pricing |
| 2025 |
~$13,200 |
Anticipated early biosimilar launches in select markets |
| 2026 |
~$12,700 |
Biosimilar competition intensifies |
| 2027 |
~$12,000 |
Price reductions stabilize as biosimilars gain market share |
| 2028+ |
~$10,500 |
Post-patent expiration, biosimilar availability influences pricing |
Note: These projections assume no drastic policy shifts or new, more effective competitors.
Key Takeaways
- The current U.S. retail price for Nivolumab remains high, with minimal reductions over recent years.
- The market is driven by multiple indications, with expansion supporting revenue growth.
- Biosimilar entry, expected post-2028, will likely lead to a 20-30% price decrease initially, with further reductions over subsequent years.
- Price negotiations and value-based care models are increasingly influencing net prices.
- Competitive landscape shifts and regulatory delays could alter projections.
FAQs
1. What are the main factors influencing Nivolumab’s pricing?
Patents and market exclusivity, biosimilar competition, negotiations with payers, and value-based pricing models are primary factors.
2. When will biosimilars for Nivolumab likely enter the market?
In the U.S., after patent expiration in 2028, with some biosimilars possibly approved by 2026 in other regions like Europe.
3. How does Nivolumab's price compare to other immune checkpoint inhibitors?
It is among the highest in the class, with list prices around $14,000 per vial, matching or exceeding competitors like Tecentriq and Keytruda.
4. Which indications are most lucrative for Nivolumab?
Non-small cell lung cancer, melanoma, and renal cell carcinoma account for the majority of sales.
5. What factors could accelerate price declines beyond biosimilar entry?
Policy reforms, value-based pricing, and reimbursement shifts could impose additional pressure, leading to earlier or deeper discounts.
Sources:
- IQVIA MultiSource Data, 2022.
- FDA drug approval archives.
- Medicare pricing and rebate data.
- Market research reports from EvaluatePharma and IQVIA.
- Patent and biosimilar regulatory status documents.
